AEMETIS INC
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
AMTX$1.59-8.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| For the year ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating activities: | ||
| Net loss | $(46,420) | $(107,758) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Share-based compensation | 7,660 | 6,410 |
| Depreciation | 6,933 | 5,535 |
| Debt related fees and amortization expense | 6,524 | 7,363 |
| Intangibles and other amortization expense | 72 | 46 |
| Accretion and other expenses of Series A preferred units | 25,313 | 9,888 |
| Warrants issued for working capital agreement | 409 | - |
| Loss on asset disposals | - | 47 |
| Loss on debt extinguishment | - | 49,386 |
| Gain on litigation | - | (1,400) |
| Loss on lease termination | - | 736 |
| Deferred tax (benefit) expense | (750) | 832 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (7,422) | 294 |
| Inventories | (13,843) | 360 |
| Prepaid expenses | 1,838 | 1,777 |
| Other assets | (2,016) | (3,941) |
| Accounts payable | 13,726 | 2,183 |
| Accrued interest expense and fees | 23,558 | 15,501 |
| Other liabilities | (1,757) | (10,125) |
| Net cash provided by (used in) operating activities | 13,825 | (22,866) |
| Investing activities: | ||
| Capital expenditures | (33,119) | (39,157) |
| Grant proceeds received for capital expenditures | 9,432 | 7,851 |
| Net cash used in investing activities | (23,687) | (31,306) |
| Financing activities: | ||
| Proceeds from borrowings | 75,482 | 69,356 |
| Repayments of borrowings | (56,130) | (26,266) |
| Lender debt renewal and waiver fee payments | (1,681) | (1,169) |
| Payments on Series A preferred financing | (30,000) | - |
| Payments on finance leases | (428) | (481) |
| Proceeds from issuance of common stock in equity offering | 21,718 | 11,987 |
| Proceeds from the exercise of stock options | 133 | 206 |
| Net cash provided by financing activities | 9,094 | 53,633 |
| Effect of exchange rate changes on cash and cash equivalents | 49 | (213) |
| Net change in cash and cash equivalents for period | (719) | (752) |
| Cash, cash equivalents, and restricted cash at beginning of period | 6,999 | 7,751 |
| Cash, cash equivalents, and restricted cash at end of period | 6,280 | 6,999 |
| Supplemental disclosures of cash flow information, cash paid: | ||
| Cash paid for interest | $9,813 | $19,515 |
| Income taxes paid | 20 | 10 |
| Supplemental disclosures of cash flow information, non-cash transactions: | ||
| Subordinated debt extension fees added to debt | 680 | 680 |
| Debt fees added to revolving lines | - | 800 |
| Fair value of warrants issued to subordinated debt holders | 1,278 | 1,939 |
| Fair value of stock issued to a related party for guarantee fees | - | 2,012 |
| Fair value of warrants issued to lender for debt issuance costs | 318 | 3,158 |
| Fair value of stock issued to lender | - | 1,335 |
| Lender debt extension, waiver, and other fees added to debt | - | 583 |
| Capital expenditures in accounts payable | 7,900 | 15,411 |
| Payment of debt added to revolving lines | - | 16,266 |
| Operating lease liabilities arising from obtaining right of use assets | - | 306 |
| Financing lease liabilities arising from obtaining right of use assets | - | 2,932 |
| Capital expenditures purchased on financing | - | 290 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.